Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1455602

Autoantibodies in Cancer: A Systematic Review of Their Clinical Role in the Most Prevalent Cancers

Provisionally accepted
Ana Montero Calle Ana Montero Calle 1Maria Garranzo-Asensio Maria Garranzo-Asensio 1Teresa Moreno Casbas Teresa Moreno Casbas 1Susana Campuzano Ruiz Susana Campuzano Ruiz 2Rodrigo Barderas Rodrigo Barderas 1*
  • 1 Carlos III Health Institute (ISCIII), Madrid, Spain
  • 2 Complutense University of Madrid, Madrid, Madrid, Spain

The final, formatted version of the article will be published soon.

    Although blood autoantibodies were initially associated with autoimmune diseases, multiple evidence have been accumulated showing their presence in many types of cancer. This has opened their use in clinics, since cancer autoantibodies might be useful for early detection, prognosis, and monitoring of cancer patients. In this review, we discuss the different techniques available for their discovery and validation. Additionally, we discuss here in detail those autoantibody panels verified in at least two different reports that should be more likely to be specific for one of each of the four most incident cancers. We also report the recent developed kits for breast and lung cancer detection mostly based on autoantibodies and the identification of novel therapeutic targets because of the screening of the cancer humoral immune response. Finally, we discuss unsolved issues that still need to be addressed for the implementation of cancer autoantibodies in clinical routine for cancer diagnosis, prognosis, and/or monitoring.

    Keywords: Humoral Immune Response, Autoantibodies, cancer autoantibodies, colorectal cancer, breast cancer, lung cancer, prostate cancer, Proteomics

    Received: 27 Jun 2024; Accepted: 31 Jul 2024.

    Copyright: © 2024 Montero Calle, Garranzo-Asensio, Moreno Casbas, Campuzano Ruiz and Barderas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Rodrigo Barderas, Carlos III Health Institute (ISCIII), Madrid, Spain

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.